Kornimate/medical-research-clean huggingface dataset:
impact of systemic manifestations/comorbidities on clinical state, prognosis, utilisation of health care resources in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the purpose of this study is to determine the prevalence and severity of extrapulmonary disorders and to quantify the impact of extrapulmonary organ manifestations on morbidity and mortality of copd patients. furthermore the investigators evaluate the relationship between systemic inflammation and organ involvement.

chronic diseases and comorbidities have an increasing impact on individual life and health care use, as exemplified in chronic obstructive pulmonary disease (copd). currently, independent, comprehensive databases allowing for an integrated view are lacking. the study will for the first time establish a large, comprehensive longitudinal database covering a broad panel of comorbidities an markers of systemic alterations. these data will be of unique value in revealing specific phenotypes of copd via patterns and risk profiles of comorbidities, enabling a more precise diagnosis and targeting of therapy, and an efficient allocation of resources.

Eligibility criteria:
inclusion criteria: * aged 40 years and older * diagnosis of copd (gold-criteria) or chronic bronchitis * informed consent * available for repeated study visits pver 18 months exclusion criteria: * having undergone big lung surgery (e.g. lung reduction, lung transplant) * moderate or severe exacerbation within the last 4 weeks * having a lung tumor * unable to walk or to understand the intention of the project

Keywords: copd register comorbidities systemic inflammation
the influence of "karate" on bleeding in hemophilic patients.

Conditions: Hemophilia A

Summary: hemophilia patients tend to lower their physical activity level due to the fear of increasing bleeding episodes. although recent literature has shown that with routine muscle strengthening and physical activity, the frequency and duration of bleeds was reduced. our study has built a routine of strength training exercises and karate training. the study is built in two stages, each stage being three months. the participants fill out a bleeding diary that includes information from the previous six months. it includes place of bleed, duration, pain level, spontaneous or traumatic bleed, factor replacement and joint limitation. before the exercise, the participants are tested for muscle strength and endurance. the bleeding diary will be filled out following the first three months and the second phase as will the muscle strength and endurance. we are hoping to see a drastic reduction of bleeding episodes occurring especially from spontaneous bleeds.

none - hemophilia patients tend to lower their physical activity level due to the fear of increasing bleeding episodes. although recent literature has shown that with routine muscle strengthening and physical activity, the frequency and duration of bleeds was reduced. our study has built a routine of strength training exercises and karate training. the study is built in two stages, each stage being three months. the participants fill out a bleeding diary that includes information from the previous six months. it includes place of bleed, duration, pain level, spontaneous or traumatic bleed, factor replacement and joint limitation. before the exercise, the participants are tested for muscle strength and endurance. the bleeding diary will be filled out following the first three months and the second phase as will the muscle strength and endurance. we are hoping to see a drastic reduction of bleeding episodes occurring especially from spontaneous bleeds.

Eligibility criteria:
inclusion criteria: * severe hemophilia. exclusion criteria: * no inhibitors.
perioperative endothelial dysfunction in patients undergoing minor abdominal surgery

Conditions: Myocardial Injury

Summary: this study on minor surgery serves to explore whether a dose-response relationship exists between surgical stress and endothelial dysfunction in the early postoperative period. the aim of this explorative and observational clinical study is to closely examine the endothelial function and its dynamics in the early postoperative period after minor surgery (lap. inguinal hernia repair). the endothelial function will be assessed indirectly by endopat and plasma biomarkers of nitric oxide bioavailability. the study will contribute to the understanding of perioperative myocardial injury, which is crucial for optimized treatment of patients at risk of cardiovascular complications.

the investigators will include 60 patients undergoing elective inguinal hernia repair. the endothelial function will be measured before surgery and 4 hours after surgery with the endopat system. the no-bioavailibility will be measured by plasma l-arginine, plasma adma and plasma biopterins.

Eligibility criteria:
inclusion criteria: * patients scheduled for a laparoscopic inguinal hernia repair * patients ≥ 18 years old exclusion criteria: * not capable of giving informed consent after oral and written information * previously included in the trial ￼￼ - surgery within 7 days of the trial

Keywords: endothelial dysfunction surgery cardiovascular complications endopat myocardial injury myocardial infarction
melatonin epigenetic potential in preventing malignant transformation of oral lichen planus

Conditions: Oral Lichen Planus

Summary: background: oral lichen planus (olp) is one of the most common oral diseases that has an unneglectable rate of malignant transformation. recently malignant transformation has been definitively linked to epigenetic changes. one of those most common changes is dna hypermethylation that causes tumor suppressor genes to downtranslate and thus carcinogenesis begins. znf582 gene hypermethylation is emerging as an exclusive biomarker to differentiate between normal and dysplastic changes that occur over the epithelium. aim: to evaluate the melatonin epigenetic potential in preventing malignant transformation of olp. material and methods: an epigenetic randomized clinical study will be conducted on 50 patients suffering from olp, recruited from the outpatient clinic of oral medicine department, alexandria faculty of dentistry, egypt. patients will be assigned to either control group who will receive topical corticosteroids and antifungal treatment, or test group who will receive melatonin supplement in addition to conventional treatment. all patients will be genetically evaluated for the level of dna hypermethylation 8 weeks after treatment, and clinically evaluated for disease severity and pain, by elsabagh scoring system 4. 8, and 12 weeks after treatment.


Eligibility criteria:
inclusion criteria: * patients clinically and histopathologically diagnosed to be suffering from olp in the following forms has been reported in the literature to have the highest potentiality for malignant transformation (plaque-type lichen , erosive lichen planus, ulcerative lichen planus), with or without histopathological dysplasia. * patients who have symptoms (i.e. pain and burning sensation) secondary to olp. exclusion criteria: * patients suspected to have lichenoid drug reaction or lichenoid contact allergy. * patients suffering from systemic diseases (such as diabetes, cardiovascular or liver disorders, renal dysfunction). * patients with findings of any physical or mental abnormality that would interfere with or be affected by the study procedure. * patients who have adverse habits of chewing tobacco and smoking. * pregnant and lactating women. * patients under treatment with corticosteroids and immunosuppressants. * patients exhibiting any skin manifestations of olp
ecmo for covid-19 vs influenza a h1n1 associated ards

Conditions: ARDS; COVID-19; H1N1 Influenza

Summary: objective: veno-venous ecmo has been used as a rescue therapy for patients with severe ards associated to influenza a h1n1 and covid19 viral pneumonia. little is known about outcome of these patients who required extracorporeal support. research question: to compare outcome of patients who required vv ecmo for covid19 and h1n1 associated ards


Eligibility criteria:
inclusion criteria: * covid-19 or influenza a h1n1 (suspected or confirmed) diagnosis * severe ards (according to berlin definition) * vv ecmo * invasive mechanical ventilation through endotracheal tube or tracheostomy exclusion criteria: • age\<18 years
stress management training in patients undergoing radiation therapy for cancer

Conditions: Anxiety Disorder; Depression; Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: stress management techniques such as muscle relaxation, guided imagery, and abdominal breathing may improve quality of life and decrease emotional distress in patients who are undergoing radiation therapy for cancer. purpose: randomized clinical trial to determine the effectiveness of stress management training in helping cancer patients cope with the emotional distress of radiation therapy.

objectives: primary * determine whether a modified version of a self-administered stress management training intervention, previously found to be of benefit in chemotherapy patients, is effective in improving quality of life and decreasing psychological distress (anxiety and depression) in patients with cancer who are undergoing radiotherapy. secondary * compare the efficacy of this intervention on improving quality of life and decreasing psychological distress (anxiety and depression) in male vs female patients. outline: this is a randomized, multicenter study. patients are randomized to 1 of 2 treatment arms. * arm i: patients receive self-administered stress management training (ssmt) in 3 stress management techniques (progressive muscle relaxation training and guided imagery, abdominal breathing, and coping skills) adapted specifically for use during radiotherapy. patients initially receive a 5-minute standardized presentation regarding the nature and purpose of ssmt. patients then receive information and instruction regarding the three stress management techniques comprising a videotape, audiotape, and brochure. patients also receive their institution's usual psychosocial care. * arm ii: patients receive their institution's usual psychosocial care only. quality of life, anxiety, and depression are assessed at baseline and then at 1, 2, and 3 weeks. intervention helpfulness is assessed at 3 weeks. projected accrual: a total of 327 patients (approximately 163 per treatment arm) will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * diagnosis of cancer * must be scheduled to receive a minimum of 12 radiotherapy treatments over a 21-day period * must not be scheduled to receive cns irradiation * must not be scheduled to receive radiotherapy as palliative care only * prostate seed implants allowed patient characteristics: age * 18 and over performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified other * able to read and speak english prior concurrent therapy: biologic therapy * not specified chemotherapy * at least 4 weeks since prior chemotherapy * no concurrent cytotoxic chemotherapy endocrine therapy * not specified radiotherapy * see disease characteristics * no prior radiotherapy surgery * not specified

Keywords: anxiety disorder depression unspecified adult solid tumor, protocol specific
to study the immunomodulating effects and safety profile of ω3 and ω6 pufa containing intravenous lipid emulsion in patients with acute on chronic liver failure

Conditions: Chronic Liver Failure

Summary: study population: patients admitted or seen in opd (out patient department), department of hepatology. study design- prospective randomized controlled trial. study period-january 2016 to may 2017 intervention- subjects will be randomized into 3 groups group a subjects will receive ω3 pufa (polyunsaturated fatty acids) (10% omegavan 100 ml). group b- will receive ω6 pufa (polyunsaturated fatty acids) (10% intralipid 100 ml). group c -placebo group monitoring and assessment- :- the following tests will be done in these patients:- 1. complete clinical examination. 2. serum electrolytes- sodium, potassium, calcium, magnesium, phosphate levels 3. bun (blood urea nitrogen) 4. serum free fatty acid levels 5. lipid profile. 6. arterial ammonia 7. arterial lactate 8. blood sugar and serum insulin levels


Eligibility criteria:
inclusion criteria: * acute on chronic liver failure (aclf) patients aged 18 years and above * patients tolerating enteral nutrition * patients with no overt sepsis - no fever, sterile blood and urine cultures, procalcitonin \<2 exclusion criteria: * active ongoing gi bleed * allergy to soya oil, eggs, peanuts or other ingredients of intralipid. * co-morbidities like diabetes mellitus, hyperlipidemia, cad and hypothyroidism. * renal failure (s.creatinine \> 2.5mg%) * pregnancy * patients with shock requiring vasopressor support * patients on anticoagulants * refusal to participate in the study

Keywords: acute
centralized pan-middle east survey on the undertreatment of hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: study objective is to evaluate the level of control of hypercholesterolemia in egypt in patients taking lipid lowering agents for at least 3 months ( with no drug change or dose amendment for a minimum of 6 weeks).

centralized pan-middle east survey on the undertreatment of hypercholesterolemia

Eligibility criteria:
inclusion criteria: * 18 years and above on current lipid lowering drug for at least 3 months with no dose change for a minimum of 6 weeks * subject must provide informed consent and comply with the survey procedures exclusion criteria: * less than 18 years less than 3 months on antidyslipidemic agent subjects who are unwilling or unable to provide informed consent

Keywords: multi-center survey patients currently on lipid-lowering pharmacological treatment level of control of hypercholesterolemia in egypt
fibrinolysis compared to thoracoscopy for pleural infection

Conditions: Pleural Infection; Empyema; Pleural Diseases; Parapneumonic Effusion

Summary: the purpose of this prospective randomized clinical trial is to compare two currently accepted standard-of-care treatment strategies: medical thoracoscopy as compared to instillation of intrapleural tissue plasminogen activator (tpa) and human recombinant deoxyribonuclease (dnase) for the management of empyema or complicated parapneumonic effusion (cppe) in adults.

background: pleural infection (empyema or complex parapneumonic effusion (cppe)) represents one of the most common clinical diagnoses encountered in clinical practice in the united states (us) it is associated with substantial morbidity and mortality despite advances in medical diagnostic and therapeutic strategies. objective: compare two standard of care treatments: tpa/dnase vs early medical thoracoscopy methods: investigators will conduct a prospective randomized clinical trial. plan is to enroll total of 32 patients and randomize those patients to either medical thoracoscopy group or fibrinolytic therapy group. follow-up will be daily until hospital discharge and at 6 and 12 weeks in the outpatient setting potential outcome and benefit: determine best strategy for treating patients with pleural infection

Eligibility criteria:
inclusion criteria: subjects \>18 years old with: evidence of empyema or complex parapneumonic effusion exclusion criteria: age \<18 years pregnancy inability to give informed written consent previous thoracic surgery or thrombolytic therapy for pleural infection medical thoracoscopy cannot be performed within 48 hours hemodynamic instability or severe hypoxemia non corrected coagulopathy homogeneously echogenic effusion on pleural ultrasonography
xenon-anesthesia on patients undergoing major liver-resection

Conditions: Liver Function After Partial Liver Resection

Summary: the aim of this study is to compare the postoperative outcome of patients undergoing major liver resection under xenon- compared to desflurane-anesthesia.

the aim of this study is to compare the postoperative liver function and additional outcome parameters of patients undergoing major liver resection under xenon- compared to desflurane-anesthesia. xenon is known to maintain hemodynamic stability and consecutive tissue perfusion. together with its potential for ischemic pre-conditioning, we hypothesize a protective effect of xenon on post-operative liver failure and ischemia/reperfusion injury.

Eligibility criteria:
inclusion criteria: * ≥ 3 segments liver resection * ≥ 18 years * both gender * american society of anesthesiologists (asa) classification i-iii * written informed consent prior to study participation exclusion criteria: subjects, fulfilling one or more of the following exclusion criteria will not be included in the study: * severe pulmonary or airway disease * severe liver disease, accompanied by a child-pugh class \>a * allergy/hypersensitivity to study medications * asa ≥ iv * patients susceptible to malignant hyperthermia * women who are pregnant, breast-feeding or women of childbearing potential not using adequate contraceptive methods * patients with preeclampsia or eclampsia * patients legally unable to give written informed consent. * patients with risk of high oxygen demand * patient with seriously impaired cardiac function * all contraindications for xenon anesthesia according to the summary of product characteristics lenoxe * patient participates in a parallel interventional clinical trial during this study or receives an investigational drug within 30 days prior to inclusion into this study

Keywords: xenon liver resection post-operative liver failure anesthetics, inhalation desflurane randomized controlled trail rct
the clonoseq® watch registry

Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell; Chronic Lymphocytic Leukemia; Multiple Myeloma; Non-hodgkin Lymphoma

Summary: this is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (all), multiple myeloma (mm), chronic lymphocytic leukemia (cll), or non-hodgkin lymphoma (nhl). this study will enroll up to 528 patients in up to 50 sites in the united states and collect data with regard to use of the clonoseq mrd assay in the management of lymphoid malignancies.

data show that detection of mrd may be important to guide treatment decisions in all, mm, cll, and nhl. however, there remains a lack of real-world evidence for making therapeutic decisions based upon mrd status. this study is designed to understand when in a patient's treatment continuum the assay is used and how clonoseq mrd data impact the treatment decisions made by investigators. all patients enrolled in the study will be followed for at least 2 yrs. demographic data and disease status will be captured at study enrollment. patients must be \>/= 18 yrs of age and able to sign informed consent. a given patient is eligible to enroll in the study if the treating physician has made the decision to use the clonoseq assay as part of that patient's routine cancer care. reasons for placing a clonoseq order and subsequent decisions made as a result of mrd data will be tracked. patient treatment will also be tracked over the course of the study in order to understand how clonoseq use is incorporated into current treatment regimens. participating centers will include sites that actively use clonoseq to manage their patients with lymphoid malignancies.

Eligibility criteria:
inclusion criteria: 1. patients must be able to provide written informed consent 2. a decision has been made by the treating provider to use the clonoseq assay as part of routine clinical care 3. age ≥ 18 years; 4. documented hematologic malignancy (any of the below): 1. mm 2. all (b and t-cell subtypes) 3. b-cell nhl (all sub types) 4. cll 5. other lymphoid malignancies (upon review and approval by study chair) exclusion criteria: patients must not meet any of the following criteria in order to be enrolled into the study: 1. concurrent enrollment in a clinical trial where treatment decisions and patterns are dictated per protocol 2. a decision has been made by the treating provider to not use the clonoseq assay as part of routine clinical care

Keywords: minimal residual disease measurable residual disease mrd clonoseq all cll mm nhl watch registry
colombia national porphyria registry

Conditions: Rare Diseases; Porphyrias

Summary: porphyria is classified as a rare disease and is produced by defects in the enzymatic activity in the biosynthesis of the heme group that leads to the over-accumulation and excretion of porphyrin precursors in hepatocytes or erythroid cells, extrahepatic or extramedullary cells, tissue, and end-organ injury. acute intermittent porphyria is the most common and severe form of hepatic porphyria, with an annual incidence of symptomatic patients of 0.13 per million people. aim: characterization of cases of acute hepatic porphyria in colombia. methods: a descriptive pilot study of patients diagnosed with acute hepatic porphyria's in colombia. patients of all age groups with a confirmed diagnosis of acute hepatic porphyria. patients with concomitant pathologies, as well as pregnant women, will also be included. patients who refuse to participate in the study will be excluded. expected results: describe the sociodemographic and clinical characteristics of patients with a diagnosis of acute hepatic porphyria, and encourage patients and/or representatives in the research agenda.

a cross-sectional descriptive observational study is carried out in adult patients diagnosed with hap in colombia, the incidence and prevalence were estimated, the clinical, socio-demographic and acute attack characteristics are described, and the health-related quality of life was evaluated with the sf-36 questionnaire.

Eligibility criteria:
inclusion criteria: - patients of all age groups with a confirmed diagnosis of acute hepatic porphyria with at least one of the following characteristics will be included: * acute symptoms consistent with disease and positive urine qualitative porphobilinogen or substantially elevated quantitative porphobilinogen. * acute symptoms compatible with the disease and decreased hmbs enzyme activity (less than 50%). * mutation in the genetic sequence of the hmbs gene. * confirmatory test that identifies the type of porphyria (analysis of total and fractionated porphyrins in urine, feces and plasma). patients with concomitant pathologies, as well as pregnant women, will also be included. exclusion criteria: * patients who refuse to participate in the study will be excluded.

Keywords: acute hepatic porphyria porphyrias quality of life